SCHEMBL18949684

SCHEMBL18949684

CCC(CC)C(=O)NC1CCN(C)CC1

nearest known ligand 0.58

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
CYP1A2 P05177 1/20 0.44
SIGMAR1 Q99720 2/20 0.42
FPR2 P25090 1/20 0.41
EPHX2 P34913 3/20 0.41
CYP2C19 P33261 1/20 0.40
USP2 O75604 2/20 0.39
TSHR P16473 1/20 0.39
SSTR4 P31391 2/20 0.39
ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21730511 0.92 USP2 (0.42) KDM4ECYP1A2SIGMAR1FPR2EPHX2
SCHEMBL13266366 0.85 CYP1A2 (0.51) KDM4ECYP1A2SIGMAR1EPHX2USP2
SCHEMBL10098777 0.84 CHRNB4 (0.54) KDM4ESIGMAR1FPR2EPHX2
SCHEMBL13266367 0.81 EPHX1 (0.49) KDM4ECYP1A2SIGMAR1EPHX2USP2
SCHEMBL23584108 0.80 SIGMAR1 (0.46) SIGMAR1EPHX2USP2
SCHEMBL5197128 0.79 EPHX1 (0.56) KDM4ECYP1A2SIGMAR1EPHX2ALDH1A1
SCHEMBL9891797 0.79 KDM4E (0.51) KDM4EFPR2EPHX2ALDH1A1
SCHEMBL24697188 0.78 HDAC7 (0.43) KDM4ESIGMAR1USP2TSHRSSTR4
SCHEMBL21695552 0.78 SMN1; SMN2 (0.47) CYP1A2SIGMAR1USP2TSHR
SCHEMBL18389999 0.78 KDM4E (0.50) KDM4ESIGMAR1FPR2EPHX2SSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731986-B2 Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2023-08-22 US disclosed
US-20230029557-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2023-02-02 US disclosed
US-11066420-B2 Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2021-07-20 US disclosed
US-20200055875-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-02-20 US disclosed
US-9695172-B2 Diazepane derivatives and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-07-04 US disclosed
US-9675697-B2 BET bromodomain inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230029557-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF ACP1, PTPRCAP, PTPRO KDM4E 1140/4885CYP1A2 4566/4885SIGMAR1 3702/4885
US-11731986-B2 Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof ACP1, PTPRCAP, PTPRO KDM4E 1140/4885CYP1A2 4566/4885SIGMAR1 3702/4885
US-20200055875-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF ACP1, PTPRCAP, PTPRO KDM4E 1140/4885CYP1A2 4566/4885SIGMAR1 3702/4885
US-11066420-B2 Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof ACP1, PTPRCAP, PTPRO KDM4E 1140/4885CYP1A2 4566/4885SIGMAR1 3702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.